Aggressive course of disease in dementia

  title={Aggressive course of disease in dementia},
  author={Serge Gauthier and Bruno Vellas and Martin R. Farlow and David Burn},
  journal={Alzheimer's \& Dementia},

Current and future therapies for Alzheimer's disease and related disorders

It is possible that a similar approach will be useful in vascular dementia, mixed Alzheimer’s disease/vascular disease, Parkinson's disease dementia, dementia with Lewy bodies and fronto–temporal dementia.

Biochemical and Radiological Markers of Alzheimer's Disease Progression.

This review summarizes the results of studies on potential biochemical and radiological markers related to AD progression and indicates that there is a lack of a reliable biomarker that enables one to stratify the risk of deterioration.

Movement Disorders in Alzheimer’s Disease

This chapter reviews mainly those movement disorders resulting from the neurodegenerative process, and psychiatric complications of AD either itself or due to the use of neuroleptics represent another source of motor symptoms.

Predicting cognitive decline in Alzheimer's disease: An integrated analysis

Neuropsychiatric Symptoms in Alzheimer’s Disease Patients: Improving the Diagnosis

The aim of this work is to discuss some aspects related to disagreements between the caregiver report and the clinician impression on neuropsychiatric symptoms of patients with Alzheimer's disease.

Apathy in Alzheimer’s disease: Contribution to a clinical view on progression of dementia

Apathy is a distinct syndrome among patients with AD and increases with global deterioration, reinforcing the hypothesis that apathy severity aggravates as the disease progresses.

RAPID progression: tool for screening aggressive course of disease (ACD) in Alzheimer dementia.

The present pilot study suggests that the Thai RAPID can be a valuable tool for the ACD screening and for progression assessment in AD patients.

Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: Interest of the Deco questionnaire

The Deco test appears to be a simple tool to alert the physician to the possibility of an aggressive course of the disease which warrants particular management and is validated as a diagnostic tool for rapid decline.

Markers of Prognosis in Neurodegenerative Dementia

The aim of this thesis is to identify, review and qualify possible indicators, including biological markers to predict course and time of survival in the two most common types of neurodegenerative dementia; AD and DLB/PDD.

Functional dependence and caregiver burden in Alzheimer's disease: a controlled trial on the benefits of motor intervention

The aim of this study was to verify if a 6‐month motor intervention programme promoted functionality in Alzheimer's patients and attenuated caregivers' burden.



Cognitive decline is faster in Lewy body variant than in Alzheimer's disease

This study demonstrates that LBV is characterized by a faster cognitive decline and accelerated mortality compared with AD.

Distinction Between Preclinical Alzheimer's Disease and Depression

OBJECTIVE: To assess the prevalence of depression in subjects with preclinical Alzheimer's disease (AD) and to investigate the possibility of differentiating subjects with preclinical AD and

Cognitive deterioration in Alzheimer’s disease: is the early course predictive of the later stages?

It is suggested that, in future clinical trials on Alzheimer's disease, a stratification of participants based on the early rate of cognitive deterioration may be considered, and a tool is provided for predicting the speed of cognitive decline of patients from a single MODA assessment.

A method for estimating progression rates in Alzheimer disease.

An easily calculable rate of early disease progression can classify patients as rapid, intermediate, or slow progressors with good predictive value, even at initial presentation.

Rate of cognitive decline and mortality in Alzheimer’s disease

Mortality in AD is strongly associated with rate of cognitive decline, and risk of death was increased more than threefold in the subgroup with mild decline, more than fivefold in those with moderately rapid decline,and more than eightfold inThose with the most rapid decline.

Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease

It is suggested that for both LBV and AD, earlier age at onset may predict a more aggressive disease course.

Rapid cognitive decline: searching for a definition and predictive factors among elderly with Alzheimer's disease.

The main objective of this review was to elaborate a proposal of definition of rapid cognitive decline in order to facilitate its applicability into ordinary medical practice and to be relevant for clinical-decision making in old patients with AD.

Measurement and prediction of functional capacity in Alzheimer's disease

The utility of a multifactorial approach to the assessment of functional capacity in Alzheimer's disease is illustrated, and data indicate that extrapyramidal symptoms and psychosis are powerful predictors of the rate of decline in basic self-care activities and cognition.

Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation

This finding is consistent with the suggestion that the K variant of butyrylcholinesterase has an important role in disease progression in AD, and this may have implications for treatment.